BiomX Inc. appoints Dr. Ehud Levi to its Advisory Board to explore security and defense opportunities, focusing on counter-UAS technologies.
Quiver AI Summary
BiomX Inc. has appointed Dr. Ehud (Udi) Levi to its newly established Advisory Board, where he will help the company explore strategic alternatives in the security and defense sectors, particularly focusing on aerial response systems and counter-UAS technologies. Dr. Levi brings over 30 years of experience in Israeli intelligence and national security, having held significant roles in Unit 8200 and the Israeli Prime Minister’s Office, where he worked on counter-terror financing and various intelligence initiatives. His extensive background includes advising on emerging threats related to unmanned systems and anti-money laundering. BiomX CEO Michael Oster emphasized the growing impact of unmanned systems on global security and expressed confidence in Dr. Levi’s ability to guide the company in navigating these strategic opportunities.
Potential Positives
- BiomX Inc. has established a new Advisory Board, enhancing its strategic capabilities in evaluating business opportunities, particularly in the security and defense sectors.
- Dr. Ehud (Udi) Levi's extensive experience in Israeli intelligence and national security positions the company to leverage insights into emerging threats and counter-UAS technologies.
- The appointment signifies BiomX's proactive approach to expanding its presence in the lucrative defense and security market amidst growing concerns over UAV threats.
- Dr. Levi’s background in financial intelligence and asset tracking may lead to valuable partnerships and transactions that align with BiomX’s strategic goals.
Potential Negatives
- The appointment of Dr. Ehud (Udi) Levi could indicate a significant shift in the company's focus towards defense and security applications, raising concerns about the reallocation of resources from its core business areas.
- BiomX's emphasis on security and defense technologies may expose the company to reputational risks, especially given the sensitive nature of its new direction and Dr. Levi's background in intelligence operations.
- The press release includes forward-looking statements that acknowledge potential risks and uncertainties, which could lead to skepticism among investors regarding the feasibility of the company's strategy in the new market segment.
FAQ
What is the role of Dr. Ehud Levi at BiomX?
Dr. Levi will support BiomX in evaluating strategic alternatives and business opportunities in security and defense, including counter-UAS technologies.
What experience does Dr. Levi bring to BiomX?
Dr. Levi has over three decades of experience in Israeli intelligence, focusing on national security and counter-terrorism efforts.
Why is BiomX expanding into security and defense?
BiomX sees opportunities in counter-UAS technologies and the evolving security landscape created by increased UAV usage globally.
What businesses will Dr. Levi help BiomX evaluate?
Dr. Levi will assist in identifying partnerships and transactions related to defense systems and unmanned aerial vehicle technologies.
How will Dr. Levi be compensated for his advisory role?
Dr. Levi's compensation will align with BiomX’s existing incentive plan for board members.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PHGE Insider Trading Activity
$PHGE insiders have traded $PHGE stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $PHGE stock by insiders over the last 6 months:
- REUVEN YEGANEH has made 0 purchases and 4 sales selling 1,650,000 shares for an estimated $8,250,000.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PHGE Hedge Fund Activity
We have seen 4 institutional investors add shares of $PHGE stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 2,378,514 shares (-95.4%) from their portfolio in Q4 2025, for an estimated $4,447,821
- MORGAN STANLEY removed 1,854,032 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $973,366
- ALYESKA INVESTMENT GROUP, L.P. removed 1,590,738 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,974,680
- AIGH CAPITAL MANAGEMENT LLC removed 1,566,944 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $822,645
- JPMORGAN CHASE & CO removed 415,865 shares (-96.7%) from their portfolio in Q4 2025, for an estimated $777,667
- DAFNA CAPITAL MANAGEMENT LLC removed 401,136 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $750,124
- BOOTHBAY FUND MANAGEMENT, LLC removed 104,463 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $195,345
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.
Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company’s expansion into security and defense applications.
Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200 of the Israel Defense Forces and later as Head of the Counter-Terror Finance Office in the Israeli Prime Minister’s Office, where he led efforts to identify, track, and disrupt illicit financial networks supporting terrorist organizations, including Project Cassandra . In addition, Dr. Levi coordinated Israeli intelligence efforts targeting Iran and other fundamentalist terrorist organizations, including efforts focused on terrorist financing and weapons-related programs. He also served as Deputy to the Director of the Mossad, under the late Meir Dagan, and holds a doctorate in Middle Eastern studies from Ben Gurion University, with a focus on fundamentalist terrorist organizations.
Following his retirement from government service in 2016, Dr. Levi led large-scale asset tracking and financial intelligence projects and has served as a special advisor to governments, financial institutions, and international corporations. He has advised governments on emerging military threats, specifically unmanned systems and counter-UAS applications in the conflict in Ukraine, as well as anti-money laundering and terrorist financing.
“Unmanned systems are rapidly reshaping the global security landscape, with low-cost, high-impact UAV capabilities now widely accessible across multiple regions and actors,” said Michael Oster, CEO of BiomX. “This includes the increasing use of UAVs by Iran and its proxies, such as Hezbollah, as well as their widespread deployment in active conflict zones like Ukraine. These threats are evolving, and here to stay. Dr. Levi’s experience operating at the intersection of intelligence, financial systems, and asymmetric threats will be valuable as we evaluate strategic opportunities in defense and counter-UAS technologies.”
“The intersection of intelligence, technology, and national security is generating real opportunity for companies willing to move decisively,” said Dr. Levi. “This is true regarding counter-UAS, defense systems, and the broader security infrastructure that governments and institutions urgently need. Having worked across these domains for over three decades, I look forward to supporting BiomX as it evaluates how to position itself in this environment.”
Dr. Levi will serve as the initial member of BiomX’s newly created Advisory Board. His compensation will be aligned with the Company’s existing incentive plan.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “anticipates,” and similar expressions are intended to identify forward-looking statements.
These statements include, but are not limited to, statements regarding the Company’s strategic direction, including potential expansion into security and defense-related technologies, potential business opportunities, and the expected contributions of Dr. Levi. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially.
These risks and uncertainties are described in the Company’s filings with the Securities and Exchange Commission. BiomX undertakes no obligation to update these statements except as required by law.